News
Iridex receives CE Mark and FDA nod for its laser delivery system
Mon, 12/10/2012 - 3:05pm
Iridex touts FDA and CE clearance for its TxCell scanning laser delivery system, a non-invasive device designed to treat serious retinal diseases.
Mountain View, Calif.-based Iridex (NSDQ:IRIX) is celebrating twin regulatory wins for its laser system to treat serious retinal diseases.
The company said it landed FDA clearance in the U.S. and the CE Mark in the EU for its TxCell scanning laser delivery system, which would help physicians deliver the laser in a multi-spot scanning mode for the treatment of serious retinal diseases, according to a press release.
